- WHO could soon approve COvaxin for emergency use
- WHO said the decision date on the COVID-19 jab is yet “to be confirmed”
The World World Health Organisation is likely to approve the India’s only indigenously developed vaccine for the deadly Coronavirus in use so far – Bharat Biotech’s Covaxin – for an Emergency Use Listing (EUL) soon.
In an update on its website, the global health organisation, which began rolling data on July 6, said the date for a decision on the Indian COVID-19 jab is yet “to be confirmed”.
According to the guidelines of the World Health organisation, the EUL is a procedure to streamline the process wherein the new products can be approved and used during public health emergencies which includes a pandemic.
Currently, the World Health organisation has approved COVID vaccines by Pfizer/ BioNTech, Astrazeneca-SK Bio/ Serum Institute of India, AstraZeneca EU, Janssen, Moderna and Sinopharm for emergency use.
The Join Managing Director (JMD) of Bharat Biotech, Suchitra Ella, had recently said that the EUL process is a step closer to the final decision on Covaxin’s “global acceptance” as the rolling data was slated to begin in July.
She retweeted company’s tweet and said, “Covaxin’s Full Marathon @ finish line soon, #powered by #Passion #Pioneering #Pathbreaking #Perseverance #positiveness #proactiveness #perfection #precision #proficiency #purposeful #progressive. Folded handsFlag of Indiaur GD wishes, trust, support. we walk the talk”
Covaxin’s Full Marathon @ finish line soon, #powered by #Passion #Pioneering #Pathbreaking #Perseverance #positiveness #proactiveness #perfection #precision #proficiency #purposeful #progressive. 🙏🏼🇮🇳ur GD wishes, trust,support. we walk the talk 😷💉 https://t.co/todyf5ZgA6— suchitra ella (@SuchitraElla) July 12, 2021
On the last date of June, Suchitra Ella tweeted that the company is working closely with WHO for emergency listing.
“We are working closely with the World Health Organisation for inclusion of Covaxin in its Emergency Use Listing. Approval from WHO is not expected to be a long drawn process as the cell line and majority of our facilities have already been audited and approved by WHO for our other vaccines in the past,” Ella tweeted.
Our vision seldom changes course, until our final mission is accomplished #Covaxin .We ensure to take forward WHO EUL process as per the universal regulatory guidelines & timelines for covid 19 vaccines. We will keep you posted every step ahead 👍🏼😷💉🇮🇳🙏🏼 pic.twitter.com/ePs1zj1vlk— suchitra ella (@SuchitraElla) June 30, 2021
Covaxin, which is India’s first indigenously developed vaccine for Coronavirus, has demonstrated the efficacy of 77.8% against symptomatic COVID-19 and 93.4% against severe disease. Bharat Biotech, the manufacturer of the jab, has announced its phase 3 clinical trials, which is yet to be peer-reviewed.
In a paper published in open access Journal medRxiv, the company said, “Efficacy analysis demonstrates Covaxin to be 77.8% effective against symptomatic Covid-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4% effective against severe symptomatic Covid-19”.